Skip to main content
main-content

Spondyloarthropathies

Axial spondyloarthritis

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

15-03-2019 | Axial spondyloarthritis | Highlight | News

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

13-03-2019 | Axial spondyloarthritis | News

Adding conventional DMARDs to TNF inhibitors may be beneficial for obese axSpA patients

Using conventional synthetic DMARDs in addition to tumor necrosis factor inhibitor therapy may result in an increased likelihood of clinical response among overweight and obese patients with axial spondyloarthritis, researchers report.

22-02-2019 | Adalimumab biosimilar | News

EMA gives nod to two adalimumab biosimilars

The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

30-01-2019 | Axial spondyloarthritis | News

Elevated fecal calprotectin linked to worse disease activity in axSpA

Elevated levels of fecal calprotectin, an indicator of gut inflammation, are associated with increased disease activity and reduced physical function in patients with axial spondyloarthritis, research shows.

21-01-2019 | Ankylosing spondylitis | News

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

21-10-2018 | Axial spondyloarthritis | ACR/ARHP 2018 | News

Online self-referral tool could help improve early SpA diagnosis

An online self-referral strategy for axial spondyloarthritis could raise awareness of the condition and improve early diagnosis, suggest findings from the OptiRef study.

28-09-2018 | Axial spondyloarthritis | News

Ustekinumab disappoints in axSpA

Three phase III trials have failed to demonstrate efficacy of the IL-12/23 inhibitor ustekinumab in patients with axial spondyloarthritis.

11-09-2018 | Spondyloarthropathies | News

Bone manifestations of PsA, nonradiographic axSpA characterized

Two studies published in Arthritis Research & Therapy describe the impact of psoriatic arthritis and nonradiographic axial spondyloarthritis on bone structure.

21-08-2018 | Axial spondyloarthritis | Review | Article

Radiologic approach to axial spondyloarthritis: Where are we now and where are we heading?

Kucybała I, Urbanik A, Wojciechowski W. Rheumatol Int 2018. doi: 10.1007/s00296-018-4130-1

27-07-2018 | Axial spondyloarthritis | Article

Widespread pain in axial spondyloarthritis: Clinical importance and gender differences

Swinnen TW et al. Arthritis Res Ther 2018; 20: 156. doi: 10.1186/s13075-018-1626-8

Knowledge of features of inflammatory back pain in primary care in the West Midlands: A cross-sectional survey in the United Kingdom

The objective of this study was to assess current practice of our local general practitioners in using clinical features to assess patients with inflammatory back pain [read more].
Adizie T et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4058-5

image credits